Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

104.60 +0.75 (+0.72%)
Streaming Delayed Price Updated: 2:38 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
42 43 Next >
3 Penny Stocks to Catapult You Into the Millionaires’ Club
These penny stocks can deliver tremendous upside from their depressed range. Wall Street analysts can back it up! 
Via InvestorPlace
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
(NVS) - Analyzing Novartis's Short Interest
Via Benzinga
A Comprehensive Study Exploring Viral Disease Diagnosis Market : Key Players BioMerieux, Prescient Medicine Holdings, Danaher
AMA released Viral Disease Diagnosis Market research study .Check what differences transitions in customer choices may bring? 
Via SBWire
Exposures COVID-19
Why Are BeiGene Shares Trading Lower Today
BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to  
Via Benzinga
US Court Issues Negative Decision On Novartis' Heart-Failure Drug Patent
Swiss pharma giant Novartis AG (NYSE: NVS)  
Via Benzinga
Why Novartis Stock Slipped on Friday
A major company product lost a key legal protection. 
Via The Motley Fool
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change That
Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions. 
Via Benzinga
3 Biotech Stocks That AI is Loving in July
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential. 
Via InvestorPlace
#blackartmatters Series And Inaugural Talk By Gallerist Lewis P. Long
Famed Harlem gallery owner, Lewis P. Long, is set to lead the first talk of #BlackArtMatters, sponsored by Morristown's revered Art in the Atrium.MORRISTOWN, N.J. - July 6, 2023 - PRLog -- Famed Harlem... 
Via PRLog
Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink
Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)... 
Via Benzinga
Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis. 
Via Investor's Business Daily
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting  
Via Benzinga
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
Generalized Myasthenia Gravis Market expected to rise | Companies- Biocon, Cartesian Therapeutics, UCB, Momenta Pharamaceuticals, HanAll Biopharma, Roche, Alexion, Novartis, Takeda, BioMarin
Via AB Newswire
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
New York Post 
Via Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck
Via Benzinga
7 Top Growth Stocks to Watch for H2 2023
Many growth stocks still haven't completely recovered from their 2022 losses, so they have plenty of opportunities to do so in H2 2023. 
Via InvestorPlace
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets
Developmental biomedical device company PetVivo Holdings Inc. (NASDAQ: PETV) makes pet medical devices and therapeutics. What kind of medical devices would 
Via MarketBeat
Pulmonary Sarcoidosis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Eilly Lilly, Novartis, aTyr Pharma, Inc., Kinevant Sciences GmbH
Via AB Newswire
Malignant Pleural Effusion Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Roche Holdings AG, Bristol Myers Squibb, Novartis, Merck
Via AB Newswire
Exposures Product Safety
Pulmonary Sarcoidosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Novartis, aTyr Pharma, SarcoMed USA, Actelion, Bellerophon, Corbus Pharma
Via AB Newswire
Exposures Product Safety
Multiple Sclerosis Market | Companies – Immune Response BioPharma, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds, Bayer HealthCare, Novartis, expected to boost the market
Via AB Newswire
Weight Loss Drugs Market May Set Epic Growth Story : Abbott Laboratories, Teva, Novartis
Stay up-to-date with Weight Loss Drugs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Porphyria Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies – Alynylm Pharmaceuticals, Novartis Pharmaceuticals, Cycle Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals
Via AB Newswire
Interstitial Lung Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Roche, Novartis, AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharma
Via AB Newswire
Exposures Product Safety
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.